This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Julio Sotelo, MD
Research Division Instituto Nacional de Neurologia y Neurocirugia Insurgentes Sur 3877 14410 Mexico 22, DF, Mexico

Arch Neurol. 1990;47(10):1059-1060.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Kramer detects some ills replicated in trials for drug treatment of neurocysticercosis conducted by us¹ and by others; each of these "ills" has been previously discussed by us,^2,3 actually, we believe that some points that for Kramer are ills, for us are the strength of our trials: A different protocol of drug therapy has to be planned for every disease considering its peculiarities, there is not a universal recipe for all drug trials; in our trials we have chosen imaging studies for evaluation of therapeutic response precisely to avoid the subjective clinical evaluation so highly recommended by Kramer that is quite misleading in the case of neurocysticercosis due to its complex clinical picture that depends on several factors related to number, location, stage of lesions, and individual immunological factors⁴; double-blind, placebo-controlled trials are useful in studies where subjective evaluation of symptoms is to be made, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?